Morgan Stanley’s Co-Diagnostics CODX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.92K | Buy |
2,877
+2,789
| +3,169% | +$8.58K | ﹤0.01% | 7078 |
|
|
2026
Q1 | $164 | Buy |
88
+15
| +21% | +$51 | ﹤0.01% | 7719 |
|
|
2025
Q4 | $371 | Sell |
73
-120
| -62% | -$1.31K | ﹤0.01% | 7560 |
|
|
2025
Q3 | $1.99K | Sell |
193
-5
| -3% | -$47 | ﹤0.01% | 7309 |
|
|
2025
Q2 | $1.67K | Sell |
198
-1
| -0.5% | -$9 | ﹤0.01% | 7259 |
|
|
2025
Q1 | $1.85K | Sell |
199
-528
| -73% | -$10.1K | ﹤0.01% | 7190 |
|
|
2024
Q4 | $16.4K | Buy |
727
+242
| +50% | +$7.64K | ﹤0.01% | 6633 |
|
|
2024
Q3 | $18.2K | Sell |
485
-189
| -28% | -$7.25K | ﹤0.01% | 6536 |
|
|
2024
Q2 | $25.3K | Buy |
674
+101
| +18% | +$3.67K | ﹤0.01% | 6380 |
|
|
2024
Q1 | $19.3K | Sell |
573
-52
| -8% | -$1.88K | ﹤0.01% | 6504 |
|
|
2023
Q4 | $24.9K | Sell |
625
-61
| -9% | -$2.15K | ﹤0.01% | 6384 |
|
|
2023
Q3 | $21.8K | Sell |
686
-268
| -28% | -$10.1K | ﹤0.01% | 6454 |
|
|
2023
Q2 | $31.8K | Sell |
954
-16,421
| -95% | -$628K | ﹤0.01% | 6386 |
|
|
2023
Q1 | $771K | Buy |
17,375
+5,135
| +42% | +$412K | ﹤0.01% | 5014 |
|
|
2022
Q4 | $925K | Sell |
12,240
-415
| -3% | -$38.9K | ﹤0.01% | 4913 |
|
|
2022
Q3 | $1.22M | Sell |
12,655
-4,207
| -25% | -$588K | ﹤0.01% | 4767 |
|
|
2022
Q2 | $2.84M | Buy |
16,862
+16,018
| +1,898% | +$2.44M | ﹤0.01% | 4258 |
|
|
2022
Q1 | $156K | Sell |
844
-1,378
| -62% | -$285K | ﹤0.01% | 6050 |
|
|
2021
Q4 | $596K | Sell |
2,222
-2,355
| -51% | -$618K | ﹤0.01% | 5438 |
|
|
2021
Q3 | $1.34M | Buy |
4,577
+296
| +7% | +$86.4K | ﹤0.01% | 4864 |
|
|
2021
Q2 | $1.06M | Buy |
4,281
+3,217
| +302% | +$827K | ﹤0.01% | 5038 |
|
|
2021
Q1 | $304K | Sell |
1,064
-1,168
| -52% | -$466K | ﹤0.01% | 5416 |
|
|
2020
Q4 | $623K | Sell |
2,232
-3,803
| -63% | -$1.41M | ﹤0.01% | 4941 |
|
|
2020
Q3 | $2.46M | Buy |
6,035
+505
| +9% | +$259K | ﹤0.01% | 3463 |
|
|
2020
Q2 | $3.21M | Sell |
5,530
-6,736
| -55% | -$3.07M | ﹤0.01% | 3119 |
|
|
2020
Q1 | $2.8M | Buy |
+12,266
| New | +$2.13M | ﹤0.01% | 3041 |
|
|
2018
Q3 | – | Sell |
-9
| Closed | -$1K | – | 6718 |
|
|
2018
Q2 | $1K | Buy |
9
+7
| +350% | +$571 | ﹤0.01% | 6582 |
|
|
2018
Q1 | $0 | Buy |
+2
| New | +$153 | ﹤0.01% | 6622 |
|
|
2017
Q4 | – | Sell |
-51
| Closed | -$10K | – | 6575 |
|
|
2017
Q3 | $10K | Buy |
+51
| New | +$7.79K | ﹤0.01% | 6168 |
|
Other funds holding CODX
AC
PAG
VF
Morgan Stanley's CODX Position: Q2 2026 in Review
Morgan Stanley increased its Co-Diagnostics (CODX) stake by 3,169% in Q2 2026, buying an estimated $8.58K and bringing the position to 2,877 shares worth $8.92K. The position accounts for ﹤0.01% of the portfolio, ranked #7078.
Morgan Stanley first reported a position in CODX in Q3 2017 and has held it in 29 quarters since. The position peaked at $3.21M in Q2 2020. 24 funds tracked by Wall St. Rank hold CODX as of Q2 2026.
- Morgan Stanley held 2,877 shares of Co-Diagnostics worth $8.92K as of Q2 2026.
- Morgan Stanley bought 2,789 Co-Diagnostics shares in Q2 2026, an estimated $8.58K.
- Co-Diagnostics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7078 holding.
- Morgan Stanley first reported a position in Co-Diagnostics in Q3 2017 and has held it in 29 quarters since.
- Morgan Stanley's Co-Diagnostics position peaked at $3.21M in Q2 2020.
- 24 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.